Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents (LH2004ME)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Completed

Conditions: Classical Hodgkin Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT06814860

LH2004ME

RC-2022-2773380 (Other Grant/Funding Number)

Details and patient eligibility

About

Background. Classical Hodgkin's lymphoma (cHL) in adolescents between 15 and 18 years shows a higher disease-related mortality and the overall prognosis is worse than both children and adults.

Objectives. To investigate the immune checkpoint inhibitors (ICPI) therapeutic targets and specific T-regulatory and cytotoxic T-cell subsets, in the subgroup of adolescent cHL patients and to investigate their prognostic power.

Methods: Retrieved formalin-fixed paraffin-embedded (FFPE) of adolescent patients diagnosed with cHL with available clinical and tested by immunohistochemistry the immune checkpoint molecules CTLA-4, LAG-3, PD-1 and PDL1 and the biological markers FOXP3 and CD8.

Enrollment: 36 patients

Sex: All

Ages: 12 to 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 12 to 18 years at diagnosis of Classical Hodgkin lymphoma.

Exclusion criteria

• Unavailability/insufficiency of histological material for diagnosis.